2019
DOI: 10.1016/j.jval.2019.04.1122
|View full text |Cite
|
Sign up to set email alerts
|

Pms11 Infliximab Costs and Reasons for Treatment Discontinuation Among Patients With Rheumatoid Arthritis Receiving Treatment in U.S. Hospitals: 2012-2015

Abstract: Objectives: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and tumor necrosis factor (TNF) blocking agents have been widely used in the treatment of SpA. Recent evidence has shown anti-TNF therapies may induce hepatic injury. Interleukin inhibitors, a newer drug class with potentially lower side effects, have recently been approved for use. We aim to assess the risk of treatment-related liver injury among patients with SpA utilizing real-world data. Methods: A retrospective, claims-based observational study wa… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles